{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-200739","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.000027+00:00","generated_at":"2026-05-31T09:17:21.381564+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aileron Q2 2024 net loss $8.9M; positive Phase 1b data for LTI-03 in IPF","bullets":["Net loss of $8.9M ($0.45 per share) vs $1.8M in Q2 2023; R&D expenses surged to $3.7M from $0.2M.","Cash $21.9M as of June 30, 2024; raised $18.2M net from May 2024 registered direct offering.","Cohort 1 of Phase 1b LTI-03 (2.5 mg BID) showed positive trends in 7 of 8 biomarkers with statistical significance in 3 fibrosis-related biomarkers.","LTI-03 was generally well-tolerated; topline results from high-dose Cohort 2 expected in Q3 2024.","Company expects cash to fund operations into second half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-200739","json":"https://secwatch.observer/filing/0001193125-24-200739.json","markdown":"https://secwatch.observer/filing/0001193125-24-200739.md","text":"https://secwatch.observer/filing/0001193125-24-200739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524200739/0001193125-24-200739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524200739/d882513d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:17:21.381564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}